Auxo Firm Directory · Independent Research Profile

Bdt Capital Partners

BDT Capital Partners, LLC is the investment-adviser affiliate of BDT & MSD Partners. Its private-capital strategy is described as providing aligned capital to family- and founder-led businesses with strong, durable fundamentals. Publicly described examples include BDT & MSD's 2025 agreement for a significant minority investment in DBG Health and agreement to acquire a majority stake in Summit Companies, while funds affiliated with BDT Capital Partners led a 2023 EquipmentShare funding round and completed a 2023 significant minority acquisition in Exyte.

Key takeaway

What stands out about Bdt Capital Partners

The public record describes BDT Capital Partners as a private-capital investor focused on family- and founder-led businesses with strong, durable fundamentals. It has publicly described aligned capital deployed through affiliated funds and co-investments. BDT & MSD's publicly announced examples include the DBG Health minority-investment agreement and Summit Companies majority-stake acquisition agreement, while BDT Capital Partners-affiliated funds led the EquipmentShare financing and completed the Exyte minority acquisition.[1][2][3][4][5]

What does Bdt Capital Partners invest in?

BDT Capital Partners, LLC is identified as the investment-adviser affiliate of BDT & MSD Partners, which was formed in 2023 through the combination of BDT & Company and MSD Partners.

The platform publicly describes partnership-driven investments backed by differentiated, patient capital, along with investment solutions for family offices, trusts, foundations, and other like-minded investors.[1][2]

BDT Capital Partners’ private-capital strategy is described as providing differentiated, aligned private capital to business owners, with a focus on family- and founder-led businesses with strong, durable fundamentals.

The firm has publicly described deploying capital through affiliated investment funds and co-investments, with an emphasis on aligned, long-term capital and support for business owners and management teams.[3]

Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.

Public size / criteria information
BDT Capital Partners stated that it had invested more than $30 billion across 43 portfolio companies through affiliated investment funds and co-investments. The stated private-capital criteria focus on family- and founder-led businesses with strong, durable fundamentals.[3]

What should a business owner evaluate before considering a transaction with Bdt Capital Partners?

An owner evaluating BDT Capital Partners may want to clarify the current private-capital mandate, preferred equity-check range, desired control position, rollover expectations, governance rights, management-continuity expectations, expected investment horizon, exit process, financing capacity, follow-on capital, fees, and the role of affiliated funds and co-investors. Public examples show both minority and majority transaction structures, but they do not establish that any particular structure or term would apply to a prospective transaction.[3][4][5][6][7]

01

What is the current private-capital fund mandate and preferred equity-check range

The strategy description identifies the private-capital focus and historical investment deployment; the preferred equity-check range is a point to clarify.[3]
02

Does the firm seek majority control, significant minority positions, or both in the relevant sector

Public transaction examples include a significant minority investment, a majority-stake acquisition agreement, and a completed significant minority acquisition.[4][5][7]
03

What rollover, governance, board, and management-continuity expectations apply

The Summit Companies announcement states that the founder and management remained shareholders and continued to lead the company, while the cited strategy materials describe support for business owners and management teams.[3][5]

What companies does Bdt Capital Partners target?

Publicly stated criteria identify family- and founder-led businesses with strong, durable fundamentals. BDT Capital Partners also stated that it had invested more than $30 billion across 43 portfolio companies through affiliated investment funds and co-investments.[3]

The private-capital strategy is described as focusing on family- and founder-led businesses with strong, durable fundamentals. The broader BDT & MSD investment platform has stated that its growth-equity activities principally target technology, consumer, and healthcare.[3]

The current official BDT & MSD site lists locations including Chicago, New York, London, Verbier, Dallas, Dubai, Menlo Park, Palm Beach, Santa Monica, Luxembourg, Denver, and Frankfurt.[1]

The sources cited for this profile do not establish a standardized platform-versus-add-on policy.

Publicly identified examples include a $290 million EquipmentShare funding round led by affiliated funds in April 2023 and the completed acquisition of a significant minority interest in Exyte in April 2023, with the Stumpf Group retaining a majority stake.

These examples describe investment activity rather than a complete portfolio list.[6][7]

  • DBG Health: On August 5, 2025, BDT & MSD entered into an agreement for a significant minority investment in DBG Global Enterprises / DBG Health. The announcement described an A$1.6 billion initial investment and access to up to A$1 billion of additional capital for future acquisitions.
  • Summit Companies: On August 4, 2025, BDT & MSD entered into an agreement to acquire a majority stake from BlackRock Long Term Private Capital. Summit’s founder and management remained shareholders and continued to lead the company.
  • EquipmentShare: On April 19, 2023, funds affiliated with BDT Capital Partners led a $290 million funding round.
  • Exyte: On April 3, 2023, funds affiliated with BDT Capital Partners completed the acquisition of a significant minority interest, while the Stumpf Group retained a majority stake.
[4][5][6][7]

What is not clear from Bdt Capital Partners's public investment criteria?

The cited Summit Companies announcement states that the transaction’s financial terms were not disclosed.

The cited DBG Health announcement describes the A$1.6 billion initial investment and access to up to A$1 billion of additional capital, but does not state BDT & MSD’s resulting ownership percentage.[4][5]

Questions to ask when evaluating Bdt Capital Partners as a buyer or investment partner

What is the current private-capital fund mandate and preferred equity-check range?
The strategy description identifies the private-capital focus and historical investment deployment; the preferred equity-check range is a point to clarify.[3]
Does the firm seek majority control, significant minority positions, or both in the relevant sector?
Public transaction examples include a significant minority investment, a majority-stake acquisition agreement, and a completed significant minority acquisition.[4][5][7]
What rollover, governance, board, and management-continuity expectations apply?
The Summit Companies announcement states that the founder and management remained shareholders and continued to lead the company, while the cited strategy materials describe support for business owners and management teams.[3][5]
What is the expected investment horizon and exit process?
The strategy is described as using aligned, long-term capital; the investment-horizon policy and exit process are points to clarify.[3]
Which current BDT Capital Partners or BDT & MSD portfolio companies or investment examples may be relevant to the business?
BDT Capital Partners has stated that it invested across 43 portfolio companies, while public materials identify selected examples including DBG Health, Summit Companies, EquipmentShare, and Exyte.[3][4][5][6][7]
How are fees, financing terms, follow-on capital, and conflicts handled across affiliated funds and co-investors?
BDT Capital Partners has publicly described deploying capital through affiliated investment funds and co-investments, and the DBG Health announcement describes access to additional capital for future acquisitions.[3][4]

Sources & research notes

Public-source research
  1. Official website / firm overview
  2. Services / capabilities
  3. Investment strategy
  4. Transaction / portfolio evidence
  5. Transaction / portfolio evidence
  6. Transaction / portfolio evidence
  7. Transaction / portfolio evidence
  8. SEC filing / regulatory record
Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.